---
title: "GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED — Ownership Dossier"
canonical: https://whiteintel.dev/entity/eaed4836-64db-5bf1-8a92-22dee20764c8
json: https://whiteintel.dev/api/public/dossier/eaed4836-64db-5bf1-8a92-22dee20764c8
identifier: oo:GB-COH-08283252
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-08283252`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/eaed4836-64db-5bf1-8a92-22dee20764c8  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/eaed4836-64db-5bf1-8a92-22dee20764c8  

## Cross-source identity

The same real-world entity, resolved across sources:

- **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED** — GLEIF · `lei:549300BBV8QORU8WX093` — https://whiteintel.dev/entity/1c13b445-f46b-503f-9db6-6ca36d2f9fe3

## Ownership & control

### Owners / controllers

- **GLAXOSMITHKLINE INTELLECTUAL PROPERTY HOLDINGS LIMITED** (beneficial owner) — 100% — https://whiteintel.dev/entity/92e37c92-f9c1-5451-9c17-cdb97df17d90
- **Glaxosmithkline Intellectual Property Holdings Limited** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/4e36bd66-9b31-4681-9b3f-301cf0bedea6

### UBO chain (walk to the ultimate owner)

A **20-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `08283252`
- **Status:** active
- **Type:** ltd
- **Incorporated:** 2012-11-06
- **Registered office:** Gsk Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, United Kingdom
- **SIC:** 64209

### Officers

- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate secretary · appointed 2012-11-06
- BARCELO IGLESIAS, Cristina — director · British · appointed 2024-09-23
- FENT, Anna Mary Harcourt — director · British · appointed 2025-07-10
- GURUNLU RUSS, Demet — director · Turkish · appointed 2024-06-25
- RIVERS, Graham Paul — director · British · appointed 2023-07-18
- WALKER, Adam — director · British · appointed 2013-03-28
- EDINBURGH PHARMACEUTICAL INDUSTRIES LIMITED — corporate director · appointed 2012-11-06
- [GLAXO GROUP LIMITED](https://whiteintel.dev/entity/bc15a382-b626-4703-b25a-5893cefaa340) — corporate director · appointed 2012-11-06
- ANDERSON, Jill Dawn — director · British · appointed 2023-03-01 · resigned 2024-06-25
- ANDRIES, Jerome Charles Maurice — director · French · appointed 2017-10-01 · resigned 2023-03-01
- BLACKBURN, Paul Frederick — director · British · appointed 2012-11-06 · resigned 2016-02-01
- DINGEMANS, Simon Paul — director · British · appointed 2012-11-06 · resigned 2019-05-01
- LA CORTE, Luigi Felice — director · Italian · appointed 2015-04-20 · resigned 2017-09-30
- MACFARLANE, Fraser Gemmell — director · British · appointed 2013-03-28 · resigned 2016-11-01
- PRIESTMAN, Kate Sophie — director · British · appointed 2016-12-09 · resigned 2022-10-28
- REINAUD, Gregory Maxime — director · British · appointed 2024-01-30 · resigned 2024-07-24
- REYNOLDS, Jemma-Louise — director · British · appointed 2024-04-04 · resigned 2025-06-27
- SHAMSI, Ziba, Dr — director · British · appointed 2022-10-28 · resigned 2023-09-13
- WHEATCROFT, James Russell — director · British · appointed 2019-07-01 · resigned 2023-07-18

### Beneficial owners (Persons with Significant Control)

- [Glaxosmithkline Intellectual Property Holdings Limited](https://whiteintel.dev/entity/4e36bd66-9b31-4681-9b3f-301cf0bedea6) — 75–100% shares · corporate PSC · United Kingdom — since 2016-04-06

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/08283252
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/08283252

## Get the full, resolved dossier (agent-callable)

The above is the free teaser. The resolved **multi-hop UBO chain**, ownership **%**, full **financial history**, itemised **assets** and the hop-by-hop **exposure path** are the paid depth — callable as tools from your agent:

```bash
npx -y @whiteintel/mcp-server   # then: get_dossier · trace_ownership_path · check_offshore_exposure
```

Or unlock a one-off cited dossier for **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED** — https://whiteintel.dev/entity/eaed4836-64db-5bf1-8a92-22dee20764c8 · pricing https://whiteintel.dev/pricing.

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED**. Human view: https://whiteintel.dev/entity/eaed4836-64db-5bf1-8a92-22dee20764c8 · Structured JSON: https://whiteintel.dev/api/public/dossier/eaed4836-64db-5bf1-8a92-22dee20764c8._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._